{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=CureVac",
    "query": {
      "sponsor": "CureVac"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T13:24:10.580Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05960097",
      "title": "A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (Low dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (Medium dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (High dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0601 mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0801 mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 692,
      "start_date": "2023-08-01",
      "completion_date": "2024-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-09-24T13:24:10.580Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Hollywood, Florida • Peoria, Illinois",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05960097"
    },
    {
      "nct_id": "NCT03164772",
      "title": "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-small Cell Lung Cancer",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "BI 1361849",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PharmaJet Tropis® device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2017-12-20",
      "completion_date": "2021-10-29",
      "has_results": true,
      "last_update_posted_date": "2022-10-10",
      "last_synced_at": "2026-09-24T13:24:10.580Z",
      "location_count": 5,
      "location_summary": "Gilbert, Arizona • Tampa, Florida • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03164772"
    },
    {
      "nct_id": "NCT05823974",
      "title": "A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "F2C22C/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2B22A/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2B22B/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2B22C/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2B22D/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2B22E/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2F22A/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2F22B/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2F22C/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2F22D/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2F22E/DL001Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "F2F23D/DL001Z-NH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2F23A/DL001Z-NH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "F2F23B/DL001Z-NH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "F2F23C/DL001Z-NH",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control 3",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "F2F22F/DL001Z",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1275,
      "start_date": "2023-04-27",
      "completion_date": "2024-12-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-23",
      "last_synced_at": "2026-09-24T13:24:10.580Z",
      "location_count": 24,
      "location_summary": "Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Valparaiso",
          "state": "Indiana"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05823974"
    },
    {
      "nct_id": "NCT05260437",
      "title": "Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CV2CoV (2 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (4 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (8 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (12 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (16 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (20 µg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2022-03-24",
      "completion_date": "2023-03-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-09-24T13:24:10.580Z",
      "location_count": 24,
      "location_summary": "Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05260437"
    },
    {
      "nct_id": "NCT07073183",
      "title": "Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous NSCLC"
      ],
      "interventions": [
        {
          "name": "CV09070101 mRNA vaccine (CVHNLC) 50 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV09070101 mRNA vaccine (CVHNLC) 100 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV09070101 mRNA vaccine (CVHNLC) 200 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV09070101 mRNA vaccine (CVHNLC) 400 µg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CureVac",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-07-30",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-24T13:24:10.580Z",
      "location_count": 2,
      "location_summary": "Fairfax, Virginia • Richmond, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07073183"
    },
    {
      "nct_id": "NCT00906243",
      "title": "RNActive®-Derived Therapeutic Vaccine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hormone Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CV9103",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2009-05",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2012-04-04",
      "last_synced_at": "2026-09-24T13:24:10.580Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00906243"
    }
  ]
}